Effect of intraperitoneal acetyl-L-carnitine (ALCAR) on anxiety-like behaviours in rats

International Journal of Neuropsychopharmacology

Volumn 8, Issue 1, 2005, Pages 65-74

  Levine, Joseph ^a   Kaplan, Zeev ^a   Pettegrew, Jay W ^b,c   McClure, Richard J ^b,c   Gershon, Samuel ^c   Buriakovsky, Igor ^a   Cohen, Hagit ^a,d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d NONE   (Israel)

Author keywords

Acetyl carnitine; Animal; Anxiety disorders; Models

Indexed keywords

LEVACECARNINE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ACETYLCARNITINE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; AROUSAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; EXPLORATORY BEHAVIOR; FEAR; MALE; MAZE LEARNING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 15244349232     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004596     Document Type: Article

References (36)

1. Adamec RE, Shallow T (1993). Lasting effects on rodent anxiety of a single exposure to a cat. Physiology & Behavior 54, 101-109.
2. Beal MF (2003). Bioenergetic approaches for neuroprotection in Parkinson's disease. Annals of Neurology 53, S39-47 (discussion S47-48).
3. Bella R, Biondi R, Raffaele R, Pennisi G (1990). Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. International Journal of Clinical Pharmacology Research 10, 355-360.
4. Cohen H, Kotler M, Kaplan Z, Matar MA, Kofman O, Belmaker RH (1997). Inositol has behavioral effects with adaptation after chronic administration. Journal of Neural Transmission 104, 299-305.
5. Cohn JB, Rickels K (1989). A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Current Medical Research and Opinion 11, 304-320.
6. Dawson GR, Tricklebank MD (1995). Use of the elevated plus maze in the search for novel anxiolytic agents. Trends in Pharmacological Science 16, 33-36.
7. Dunn RW, Corbett R, Fielding S (1989). Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. European Journal of Pharmacology 169, 1-10.
8. Fariello RG, Ferraro TN, Golden GT, DeMatti M (1988). Systemic acetyl-L-carnitine elevates nigral levels of glutathione and GABA. Life Sciences 43, 289-292.
9. Farrell S, Vogel J, Bieber LL (1986). Entry of acetyl-L-carnitine into biosynthetic pathways. Biochimica et Biophysica Acta 876, 175-177.
10. 14C]GABA release and uptake from amygdaloid and hippocampal slices in the rat. Neuropharmacology 32, 1333-1336.
11. Fernandez E, Pallini R, Gangitano C, Del Fa A, Olivieri-Sangiacomo C, Sbriccoli A, Ricoy J, Rossi GF (1990). Studies on the degenerative and regenerative phenomena occurring after transection and repair of the sciatic nerve in rats: effects of acetyl-L-carnitine. International Journal of Clinical Pharmacology Research 10, 85-99.
12. Fernandez E, Pallini R, Lauretti L, Mangitano C, Del Fa A, Olivieri-Sangiacomo C, Sbriccoli A, Rossi GF (1992). Levocarnitine acetyl prevents cell death following long-term section of the vagus nerve in rats. International Journal of Clinical Pharmacology Research 12, 289-297.
13. File SE (1993). The interplay of learning and anxiety in the elevated plus-maze. Behavioural Brain Research 58, 199-202.
14. Fulgente T, Onofrj M, Del Re ML, Ferracci F, Bazzano S, Ghilardi MF (1990). Laevo-acetylcarnitine (Nicetile®) treatment of senile depression. Clinical Trials Journal 27, 155-163.
15. Garzya G, Corallo D, Fiore A, Lecciso G, Petrelli G, Zotti C (1990). Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs under Experimental and Clinical Research 16, 101-106.
16. Gecele M, Francesetti G, Meluzzi A (1991). Acetyl-L-carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol. Dementia 2, 333-337.
17. Ghirardi O, Caprioli A, Ramacci MT, Angelucci L (1994). Effect of long-term acetyl-L-carnitine on stress-induced analgesia in the aging rat. Experimental Gerontology 29, 569-574.
18. Hogg S (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacology, Biochemistry, and Behavior 54, 21-30.
19. Humble M, Wistedt B (1992). Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. International Clinical Psychopharmacology 6, 21-39.
20. 11C]acetyl-L-carnitine into the brain: a PET study. Biochemical and Biophysical Research Communications 231, 488-193.
21. Levine J, Cole DP, Chengappa KN, Gershon S (2001). Anxiety disorders and major depression, together or apart. Depression and Anxiety 14, 94-104.
22. Markowska AL, Ingram DK, Barnes CA, Spangler EL, Lemken VJ, Kametami H, Yee W, Olton DS (1990). Acetyl-L-carnitine. 1: Effects on mortality, pathology and sensory-motor performance in aging rats. Neurobiology of Aging 11, 491-498.
23. McKay Hart A, Brannstrom T, Wiberg M, Terenghi G (2002). Primary sensory neurons and satellite cells after peripheral axotomy in the adult rat: timecourse of cell death and elimination. Experimental Brain Research 142, 308-318.
24. Nasca D, Zurria G, Aguglia E (1989). Action of acetyl-L-carnitine in association with mianserine on depressed old people. New Trends in Clinical Neuropharmacology 3, 225-230.
25. Parnetti L, Gaiti A, Mecocci P, Cadini D, Senin U (1992). Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. European Journal of Clinical Pharmacology 42, 89-93.
26. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ (1995). Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiology of Aging 16, 1-4.
27. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disorders 4, 61-66.
28. Pettegrew JW, Levine J, McClure RJ (2000). Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Molecular Psychiatry 5, 616-632.
29. Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR (1994). Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiology of Aging 15, 117-132.
30. Ramacci MT, De Rossi M, Lucreziotti MR, Mione MC, Amenta F (1988). Effect of long-term treatment with acetyl-L-carnitine on structural changes of ageing rat brain. Drugs under Experimental and Clinical Research 14, 593-601.
31. Ramos R, Gentil V, Gorenstein C (1993). Clomipramine and initial worsening in panic disorder: Beyond the 'jitteriness syndrome'. Journal of Psychopharmacology 7, 265-269.
32. Tempesta E, Casella L, Pirrongelli C, Janiri L, Calvani M, Ancona L (1987). L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs under Experimental and Clinical Research 13, 417-423.
33. Thai LJ, Carta A, Clarke WR, Ferns SH, Friedland RP, Petersen RC, Pettegrew JW, Pfeiffer E, Raskind MA, Sano M, Tuszynski MH, Woolson RF (1996). A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 47, 705-711.
34. Tolu P, Masi F, Leggio B, Scheggi S, Taglimonte A, De Montis MG, Gambarama C (2002). Effects of long-term acetyl-L-carnitine administration in rats. 1. Increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. Neuropsychopharmacology 27, 410.
35. Villardita C, Smirni P, Vecchio I (1983). Acetyl-L-carnitine in depressed geriatric patients. European Review for Medical and Pharmacological Sciences 6, 1-12.
36. Wall PM, Messier C (2001). Methodological and conceptual issues in the use of the elevated plus-maze as a psychological measurement instrument of animal anxiety-like behavior. Neuroscience and Biobehavioral Reviews 25, 275-286.